Core Viewpoint - The initial public offering (IPO) of Bokan Vision Pharmaceutical Co., Ltd. (02592.HK) on the Hong Kong Stock Exchange faced a significant decline, with shares opening at HKD 9.50 and closing at HKD 6.20, representing a drop of 38.61% [1] Group 1: Company Overview - Bokan Vision is a clinical-stage ophthalmic biotechnology company focused on developing various therapies, with its core product being CBT-009, an atropine eye preparation for treating myopia in adolescents [1] - The total number of shares issued at the time of listing was 838,892,874 [2] Group 2: IPO Details - The final offer price for the shares was HKD 10.10, raising a total of HKD 611.88 million, with a net amount of HKD 522.21 million after deducting estimated listing expenses of HKD 89.67 million [2] - The number of shares offered was 60,582,000, with 12,115,500 shares allocated for public offering in Hong Kong and 48,466,500 shares for international offering [2] Group 3: Use of Proceeds - The net proceeds from the global offering are intended for ongoing clinical research and development activities for core products CBT-001 and CBT-009, as well as funding for production facilities, commercialization activities, and general corporate purposes [2] Group 4: Financial Performance - Bokan Vision has not recorded any revenue and has faced significant business failure risks, with net losses of USD 66.84 million, USD 129.42 million, and USD 99.13 million for the years 2022 to 2024, totaling USD 295.39 million [5] - Research and development expenditures for the years 2022, 2023, and 2024 were USD 15.3 million, USD 27.5 million, and USD 37.9 million, respectively [5] - The net cash used in operating activities for the same years was USD 20.05 million, USD 22.51 million, and USD 26.52 million [6][7]
拨康视云上市募6亿港元首日破发 龚虹嘉亏5600万港元